DHR · News · 20261022N
Regulatory Approval Milestones
DANAHER CORP /DE/ · 2026-10-22 · Importance 38 · Surprise 60 · In source text
Danaher subsidiary Masimo received U.S. Food and Drug Administration clearance for AI-enabled atrial fibrillation detection in its Radius VSM wearable monitor. The feature uses artificial intelligence to identify potential AFib episodes in acute-care settings. The clearance adds a digital monitoring capability to Danaher's diagnostics portfolio.
Key facts
- Masimo, a Danaher subsidiary, received FDA clearance for AI-enabled atrial fibrillation detection in its Radius VSM wearable monitor source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | Masimo, a Danaher subsidiary, received FDA clearance for AI-enabled atrial fibrillation detection in its Radius VSM wearable monitor |